(1S,4S)-2-methyl-5-(5-phenylpyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane | 1236071-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (1S,4S)-2-methyl-5-(5-phenylpyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane
• CAS: 1236071-76-3
• 化学式: C₁₆H₁₈N₄
• 分子量: 266.346
• InChiKey: OODPDBZXZQDRMJ-GJZGRUSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (1S,4S)-2-(5-bromopyrimidin-2-yl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane 、 苯硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 10.0h， 以70%的产率得到(1S,4S)-2-methyl-5-(5-phenylpyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane
  参考文献：
  名称：

  Syntheses and structure–activity relationship (SAR) studies of 2,5-diazabicyclo[2.2.1]heptanes as novel α7 neuronal nicotinic receptor (NNR) ligands

  摘要：

  Biaryl substituted 2,5-diazabicyclo[2.2.1]heptanes have been synthesized and tested for their affinity toward alpha 7 neuronal nicotinic receptors (NNRs). SAR studies established that 5-N-methyl substituent, heteroaryl linker and the nature of terminal aryl group are critical for the ligand to achieve potent alpha 7 NNR agonist activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.105

文献信息

• Syntheses and structure–activity relationship (SAR) studies of 2,5-diazabicyclo[2.2.1]heptanes as novel α7 neuronal nicotinic receptor (NNR) ligands
  作者：Tao Li、William H. Bunnelle、Keith B. Ryther、David J. Anderson、John Malysz、Rosalind Helfrich、Jens H. Grønlien、Monika Håkerud、Dan Peters、Michael R. Schrimpf、Murali Gopalakrishnan、Jianguo Ji

  DOI：10.1016/j.bmcl.2010.04.105

  日期：2010.6

  Biaryl substituted 2,5-diazabicyclo[2.2.1]heptanes have been synthesized and tested for their affinity toward alpha 7 neuronal nicotinic receptors (NNRs). SAR studies established that 5-N-methyl substituent, heteroaryl linker and the nature of terminal aryl group are critical for the ligand to achieve potent alpha 7 NNR agonist activity. (C) 2010 Elsevier Ltd. All rights reserved.